Where does iMEDI Plus Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), iMEDI Plus Inc. ranks #40,864 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does iMEDI Plus Inc. hold?

iMEDI Plus Inc. holds 6 US utility patents granted between 2017 and 2019, spanning 7 technology areas.

What is iMEDI Plus Inc.'s Innovation Score?

iMEDI Plus Inc. has an Innovation Score of 26.7 out of 100 (21st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does iMEDI Plus Inc. focus on?

iMEDI Plus Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 4 patents. Grants appear in 7 CPC subclasses total.

Is iMEDI Plus Inc.'s patent grant rate increasing or decreasing?

iMEDI Plus Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for iMEDI Plus Inc.'s patents?

iMEDI Plus Inc.'s patents average 17.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the iMEDI Plus Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

iMEDI Plus Inc.

USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, recorded in grant years 2017–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, imedi ranks #40,864 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 7 technology areas.

#40,864
of 49,997 US assignees by volume: 21st percentile
by Innovation Score (26.7/100): 17.7
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R40864 · Foreign Corporation #40,864 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #40,864/49,997
PHOTO-FINISH iBenzer
CPC-NARROW A61B · 7 areas
INNOV-THIN 26.7/100
CLAIMS-RICH 17.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: iBenzer Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
iMEDI Plus · this assignee

27
3D Lighting… · lowest

7

What this shows imedi's Innovation Score is 26.7/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where imedi's grants concentrate

iMEDI Plus Inc. is a focused PatentsView assignee: 7 CPC subclasses with 66.7% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, imedi sits between iBenzer Inc. and iSpot.tv, Inc..

ibenzer

6
icad

6
icell Gene Therap…

6
idonate

6
imicrodata

6
iographer

6
irepertoire

6
ispot tv

6
imedi Plus ◀

6

What this shows iMEDI holds 6 patents at rank #44,259, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near iMEDI

By rank, the assignees closest to #44,259 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in iMEDI's primary technology class.

imedi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 21st percentile higher than 21% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

iMEDI Plus Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	33.3%
2018	2	33.3%
2019	2	33.3%

Which technologies does iMEDI Plus Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 4

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 3

H04R - Loudspeakers, Microphones, Gramophone Pick-ups OR Like Acoustic Electromechanical TRANSDUCERS; Deaf-aid SETS; Public Address Systems 3

G10L - Speech Analysis Techniques OR Speech SYNTHESIS; Speech RECOGNITION; Speech OR Voice Processing TECHNIQUES; Speech OR Audio Coding OR Decoding 3

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

G01H - Measurement OF Mechanical Vibrations OR Ultrasonic, Sonic OR Infrasonic Waves 1

G01S - Radio DIRECTION-FINDING; Radio NAVIGATION; Determining Distance OR Velocity BY USE OF Radio WAVES; Locating OR Presence-detecting BY USE OF THE Reflection OR Reradiation OF Radio WAVES; Analogous Arrangements Using Other Waves 1

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#40,864

of 49,997 tracked assignees

Innovation Score

26.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

iMEDI Plus Inc.'s patent record in context - here's where to go next.

iMEDI Plus Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 66.7% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #40,864 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare iMEDI Plus Inc. against iBenzer Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.